| Literature DB >> 15978128 |
Ines Gockel1, Sina Heckhoff, Claudia M Messow, Werner Kneist, Theodor Junginger.
Abstract
BACKGROUND: The goal of the present analysis was to investigate the long-term prognosis for adenocarcinoma of the esophagus treated with either the transhiatal (TH) or the transthoracic (TT) operative approach.Entities:
Year: 2005 PMID: 15978128 PMCID: PMC1182399 DOI: 10.1186/1477-7819-3-40
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Clinicopathological features
| 61 (28–78) | 63 (28–78) | 60 (35–75) | 0.199 | |||||||
| U-test | ||||||||||
| 62 | 145 | 42.8% | 44 | 99 | 44.4% | 18 | 46 | 39.1% | 0.592 | |
| 83 | 145 | 57.2% | 55 | 99 | 55.6% | 28 | 46 | 60.9% | ||
| Fisher's exact test | ||||||||||
| 131 | 149 | 87.9% | 94 | 102 | 92.2% | 37 | 47 | 78.7% | 0.029 | |
| 18 | 149 | 12.1% | 8 | 102 | 7.8% | 10 | 47 | 21.3% | ||
| Fisher's exact test | ||||||||||
| 1 | 149 | 0.7% | 0 | 103 | 0.0% | 1 | 46 | 2.2% | ||
| 15 | 149 | 10.1% | 8 | 103 | 7.8% | 7 | 46 | 15.2% | 0.155 | |
| 133 | 149 | 89.3% | 95 | 103 | 92.2% | 38 | 46 | 82.6% | ||
| Chi-Square (Pearson) | ||||||||||
| 28 | 150 | 18.7% | 27 | 103 | 26.2% | 1 | 47 | 2.1% | ||
| 39 | 150 | 26.0% | 34 | 103 | 33.0% | 5 | 47 | 10.6% | <0.0005 | |
| 77 | 150 | 51.3% | 41 | 103 | 39.8% | 36 | 47 | 76.6% | ||
| 6 | 150 | 4.0% | 1 | 103 | 0.9% | 5 | 47 | 10.6% | ||
| Chi-Square (Pearson) | ||||||||||
| 51 | 146 | 34.9% | 41 | 100 | 41.0% | 10 | 46 | 21.7% | 0.027 | |
| 95 | 146 | 65.1% | 59 | 100 | 59.0% | 36 | 46 | 78.3% | ||
| Fisher's exact test | ||||||||||
| 105 | 149 | 70.5% | 75 | 102 | 73.5% | 30 | 47 | 63.8% | 0.250 | |
| 44 | 149 | 29.5% | 27 | 102 | 26.5% | 17 | 47 | 36.2% | ||
| Fisher's exact test | ||||||||||
| 62 | 149 | 41.6% | 53 | 102 | 52.0% | 9 | 47 | 19.2% | <0.0005 | |
| 87 | 149 | 58.4% | 49 | 102 | 48.0% | 38 | 47 | 80.9% | ||
| Chi-Square (Pearson) | ||||||||||
| 10 | 146 | 6.9% | 8 | 100 | 8.0% | 2 | 46 | 4.4% | 0.167 | |
| 43 | 146 | 29.5% | 32 | 100 | 32.0% | 11 | 46 | 23.9% | ||
| 76 | 146 | 52.1% | 46 | 100 | 46.0% | 30 | 46 | 65.2% | ||
| 17 | 146 | 11.6% | 14 | 100 | 14.0% | 3 | 46 | 6.5% | ||
| Chi-Square (Pearson) | ||||||||||
| 69 | 143 | 48.3% | 52 | 98 | 53.1% | 17 | 45 | 37.8% | 0.225 | |
| 62 | 143 | 43.4% | 39 | 98 | 39.8% | 23 | 45 | 51.1% | ||
| 12 | 143 | 8.4% | 7 | 98 | 7.1% | 5 | 45 | 11.1% | ||
| Chi-Square (Pearson) | ||||||||||
Morbidity and mortality
| median (range) | 254 | (160–485) | 335 | (240–540) | <0.0005 | |||
| (min) | U-test | |||||||
| median (range) | 800 | (0–7500) | 1000 | (200–5000) | 0.002 | |||
| (ml) intraoperatively | U-test | |||||||
| median (range) | 0 | (0–6) | 1 | (0–14) | 0.128 | |||
| (PRBC) intraoperatively | U-test | |||||||
| 44 | 103 | 7 | 47 | 0.001 | ||||
| Fisher | ||||||||
| 22 | 102 | 20 | 47 | 0.011 | ||||
| Fisher | ||||||||
| 62 | 103 | 25 | 47 | 0.477 | ||||
| Fisher | ||||||||
| (days) | median (range) | 8 | (2–107) | 8 | (1–97) | 0.566 | ||
| U-test | ||||||||
| (days) | median (range) | 21 | (14–126) | 20 | (13–107) | 0.646 | ||
| 3 | 103 | 7 | 47 | 0.011 | ||||
| Fisher | ||||||||
| 2 | 100 | 7 | 47 | 0.005 | ||||
| Fisher | ||||||||
Lymph node (LN) dissection
| median | range | mean | median | range | mean | U-test | |
| total LN dissected | 19 | (0–55) | 21.3 | 31 | (2–94) | 32.4 | <0.0005 |
| positive LN dissected | 2 | (0–33) | 5.4 | 4 | (0–76) | 7.9 | 0.030 |
| total abdominal LN | 14 | (0–48) | 16.4 | 11 | (0–51) | 12.0 | 0.017 |
| positive abdominal LN | 1 | (0–28) | 3.4 | 1 | (0–17) | 3.1 | 0.802 |
| total thoracic LN | 3 | (0–42) | 5.1 | 19 | (2–83) | 20.2 | <0.0005 |
| positive thoracic LN | 0 | (0–30) | 1.5 | 2 | (0–67) | 4.8 | <0.0005 |
| LN ratio total | 0.11 | (0–0.86) | 0.20 | 0.17 | (0–0.81) | 0.24 | 0.160 |
| LK ratio abdominal | 0.10 | (0–0.89) | 0.17 | 0.15 | (0–1) | 0.25 | 0.197 |
| LK ratio thoracic | 0.00 | (0–1) | 0.22 | 0.11 | (0–1) | 0.24 | 0.156 |
Prognosis
| total | TT | 46 | 16 | 13.6% | 0.018 |
| TH | 103 | 24 | 32.1% | ||
| curative (R0) | TT | 36 | 17 | 17.6% | 0.045 |
| TH | 94 | 28 | 35.1% | ||
| palliative (R1) | TT | 10 | 9 | - | 0.778 |
| TH | 8 | 8 | - | ||
| R0 pN0 | TT | 9 | 27 | 22.2% | 0.072 |
| TH | 40 | 67 | 54.1% | ||
| R0 pN1 | TT | 26 | 14 | 14.3% | 0.430 a |
| <19 thor. LN | 12 | 17 | 16.7% | 0.829 b | |
| >/ = 19 thor. LN | 14 | 8 | - | ||
| TH | 51 | 16 | 22,4% | 0.703 c | |
| R0 pN1 T1-2 | TT | 4 | 14 | 25.0% | 0.357 |
| TH | 21 | 28 | 33.3% | ||
| R0 pN1 T3-4 | TT | 22 | 9 | 12.2% | 0.793 |
| TH | 30 | 10 | - | ||
| R0 pN1 ASA 1–2 | TT | 11 | 16 | 20.0% | 0.345 |
| TH | 23 | 19 | 33.3% | ||
| R0pN1 ASA 3–4 | TT | 15 | 9 | 10.3% | 0.999 |
| TH | 25 | 10 | - | ||
| R0 middle third | TT | 4 | 5 | 25% | 0.931 |
| (tumor localization) | TH | 8 | 24 | 15% | |
| R0 lower third | TT | 32 | 17 | 17.1% | 0.044 |
| (tumor localization) | TH | 86 | 30 | 37.9% | |
TT: Transthoracic, TH: Transhiatal
a = (TT vs. TH)
b= (TT intern)
c = (TT thor. LN vs. TH)
Figure 1Kaplan-Meier survival curves for patients with adenocarcinoma and R0 resection undergoing transhiatal (TH) and transthoracic (TT) esophagectomy.
Figure 2Correlation between long-term survival and the number of dissected thoracic lymph nodes (LN) for curative (R0) resected, nodal positive (pN1) patients (n = 77) with adenocarcinoma of the esophagus.
Multivariate analysis of prognostic factors for survival
| -R1 and R2 vs. R0 | 1.368 | 0.772 | 0.2424 | 0.284 |
| -pT2 vs. pT1 | 2.418 | 0.952 | 6.144 | 0.063 |
| -pT3 and pT4 vs. pT1 | 3.930 | 1.569 | 9.847 | 0.003 |
| -pN1, 2 vs. pN0 | 1.398 | 0.776 | 2.526 | 0.267 |
| G2 vs. G1 | 0.731 | 0.264 | 2.021 | 0.545 |
| G3 vs. G1 | 0.993 | 0.370 | 2.666 | 0.989 |
| G4 vs. G1 | 1.082 | 0.348 | 3.360 | 0.892 |
| ASA III vs. ASA II | 1.100 | 0.680 | 1.779 | 0.699 |
| ASA IV vs. ASA II | 1.391 | 0.544 | 3.558 | 0.491 |
| 1.782 | 1.096 | 2.898 | ||
| TT vs. TH | 0.937 | 0.592 | 1.482 | 0.781 |
| 0.997 | 0.972 | 1.023 | ||
Multivariate analysis of three-year survival
| TT vs. TH | 1.931 | 0.573 | 6.514 | 0.289 |
| -IIa vs. I | 1.866 | 0.459 | 7.583 | 0.383 |
| -IIb vs. I | 20.350 | 2.132 | 194.254 | 0.009 |
| -III vs. I | 5.967 | 1.400 | 25.439 | 0.016 |
| -IV vs. I | 46.422 | 5.071 | 424.994 | 0.001 |
Odds ratios are to be interpreted as odds for death so that they are interpretable in the same way as the hazard ratios in Table 5.
Multivariate analysis of five-year survival
| TT vs. TH | 0.716 | 0.143 | 3.594 | 0.685 |
| -IIa vs. I | 5.483 | 0.796 | 37.788 | 0.084 |
| -IIb vs. I | 8.575 | 0.850 | 86.488 | 0.068 |
| -III vs. I | 12.133 | 1.626 | 90.526 | 0.015 |
| -IV vs. I | 28.124 | 2.773 | 285.211 | 0.005 |
Odds ratios are to be interpreted as odds for death so that they are interpretable in the same way as the hazard ratios in Table 5.